

15 May 2018 | News

QUOTED. May 15, 2018. Thomas Rodgers.

by

Liquid biopsy marquee player Grail Inc. has reported results of several proof-of-concept approaches to cancer screening that achieved high specificity, and a handful of smaller-scale cancer-specific tests are already available. See what Thomas Rodgers of Grail investor McKesson Ventures had to say about it here.

"If with a simple annual blood test someone who feels completely healthy could identify that they might have an early-stage malignant tumor, that would obviously be revolutionary."

–Thomas Rodgers, senior VP and managing director, McKesson Ventures

- Find out more: [Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?](#)

[Click here](#) for a free trial of *Medtech Insight*